Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. - Wikidata - awgldk - TriplyDB

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

http://www.wikidata.org/entity/Q33713689

about

Oligonucleotide therapeutic approaches for Huntington disease A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice Huntington's disease: the past, present, and future search for disease modifiers.Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy Mechanisms of RNA-induced toxicity in CAG repeat disorders Pluripotent stem cells models for Huntington's disease: prospects and challenges Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice Current prospects for RNA interference-based therapies Epigenetic mechanisms of neurodegeneration in Huntington's disease p120-catenin is necessary for neuroprotection induced by CDK5 silencing in models of Alzheimer's disease Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.A fully humanized transgenic mouse model of Huntington disease.Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis.Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype.Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells.Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression Oligonucleotide-based strategies to combat polyglutamine diseases.Temporal differences in microRNA expression patterns in astrocytes and neurons after ischemic injury.Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.Rhes suppression enhances disease phenotypes in Huntington's disease mice Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1 Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells Mesenchymal stem cells for the treatment of neurodegenerative disease.Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.

P2860

Q22306293-0A437C64-61FD-4426-B7EC-241397E57E24 Q24620388-2CCCA72C-1C97-4EAA-A186-1A4112CEA479 Q24626259-1699EB92-EB7C-4FBE-B05E-A7F121A2142E Q24628256-20C846BD-1BCA-419D-93E1-54E169094259 Q26830039-9CD46A43-C7F2-4D68-B877-32AF39BBE0DC Q26849677-66D436F5-F5BC-44A6-8DE6-06E4AA829DA9 Q26860030-CC7C8ED7-A08F-45E3-B787-FEEB14DFC524 Q26860151-4F3D24C7-4A12-4A76-822B-1DA458620A0D Q27005950-BC0D504A-B84D-4C5A-9834-C42519C71367 Q27317421-380FB53B-C6EE-4809-B871-F04FCE285338 Q27324212-80CFD403-DC90-40EE-B03A-40C3637C8048 Q27324749-7E95CB80-BD7D-4A15-96B2-94B1911B549B Q28235733-7FE42E5F-64A7-44AA-B30F-BFF5822A4DD1 Q28297936-AC2DD347-E8E8-46D7-82B5-1436CF113847 Q28386238-F15D1411-A4C5-4A36-A4BE-78C3095B553D Q28542911-982394E2-BB44-4DDA-932E-A39139E18FB6 Q28546047-199B7E51-88C5-4B4A-B60C-DBEBB9C5D357 Q30438915-CE90605E-D8DD-4463-83A3-28DC1CD1CF9B Q30493159-90D03618-F499-4BF3-8155-44B9304405B8 Q30537951-FCB88FF5-4D93-4D7D-945A-DEF84101E9FB Q30848992-D7F1F47F-4247-47AA-8083-3FFCEF02BB14 Q33507519-91248683-7C5C-405A-9471-C14CE6D80606 Q33594270-565ECE9F-4206-4F9D-864A-4575F9FD8840 Q33632395-0F476E78-5C4D-4E02-AF1F-2159E85AA702 Q33752590-11B6F4EE-C289-4A90-A406-6BE58ACBDD35 Q33755845-B0E8F156-9036-48E3-A54F-E509FEB57B41 Q33791247-0FFAA2B7-4362-4EF4-BCF9-714DC20DC7EB Q33836761-74591707-810D-4F2F-B2BF-5515AC395C13 Q33945342-41477FD9-826B-4D7B-B166-4DB953677034 Q34071922-98F85CCE-CCE0-4664-B1FE-E2E1B38CC8B7 Q34159111-541831E3-A6D6-4B89-A340-CA54FE95CDE7 Q34187525-E676A859-50E6-415F-9873-67D4361C086D Q34221351-96BBCAA5-98DA-4A66-9A4E-67EE5BE0E396 Q34235172-0DDF7B64-A1C1-4209-8DED-AD5012CAC931 Q34283652-BCB1326B-19CC-4971-8DB0-C75907E726DD Q34397572-0A95AE38-EE0E-47F3-B95D-E8A89D79A64F Q34463222-98FD1295-FEAF-4F50-9138-48D6CFE932FF Q34469493-A731664A-D183-41C5-B0B3-B36A8EA636B1 Q34473474-D0A1568D-26A5-4732-A705-178FCED964EC Q34492631-DC6BC2C2-76D7-4FDD-AC27-7CD48445466F

P2860

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

http://www.wikidata.org/entity/Q33713689

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Nonallele-specific silencing o ...... in Huntington's disease mice.

@ast

Nonallele-specific silencing o ...... in Huntington's disease mice.

@en

type

label

Nonallele-specific silencing o ...... in Huntington's disease mice.

@ast

Nonallele-specific silencing o ...... in Huntington's disease mice.

@en

prefLabel

Nonallele-specific silencing o ...... in Huntington's disease mice.

@ast

Nonallele-specific silencing o ...... in Huntington's disease mice.

@en

P1433

Q33713689-51239501-A499-4613-B12B-3A6EE25434EB

P1476

Q33713689-98DA7E33-B38D-4C59-B258-564CFED8C43D

P2093

Q33713689-34A9EF21-70F7-4E89-8F23-96F4656CF3F0

Q33713689-3531ED5C-8AB8-4764-BF3C-467418472930

Q33713689-38F67CB8-6063-4932-B93F-5E5D413574A4

Q33713689-5461F32C-D2EB-4147-9EBF-A3EB8175753E

Q33713689-B896FFD5-DE91-458E-A2BB-9226246505B9

Q33713689-D4B61881-02BE-4FDD-BC85-C26C8F9E26C8

P2860

Q33713689-067F5518-EED0-4251-A9C4-03A0E70B66DD

Q33713689-0845E7C0-0C42-47B5-AEF0-9BAF81203219

Q33713689-12EA2114-171A-4CA7-B8D3-DF5C4E7715EE

Q33713689-14BABF79-0058-4DF7-A923-E2E1470F9CE6

Q33713689-15E746DF-9F63-4321-86E6-880558E25AF2

Q33713689-1E226406-761B-41EF-BCF0-1E0A51C3436C

Q33713689-1F566D77-2BAB-4B6A-B916-8B220EEF4DEF

Q33713689-295B2DEB-70BC-4E13-A291-30F760018E84

Q33713689-31B557ED-4F96-41A0-BCB4-00318FC9DFC7

Q33713689-361BE9B8-49A7-466D-A9EB-92F7D4D989FB

P304

Q33713689-4F0FEBF2-F56C-4E3B-AA75-EBC96F961BE9

P31

Q33713689-2FEAB47F-7D4E-4959-9C5A-893012FE794C

P356

Q33713689-B0BD767B-5D80-43A0-B07E-712E309426D4

P433

Q33713689-3ED4C87B-14E1-4674-B6FC-2288496345E3

P478

Q33713689-DC25131B-E27E-4C8A-A379-CF97243A2A62

P50

Q33713689-466DF621-4A9F-46BA-8320-44E571088CEE

P577

Q33713689-EE01A3D4-CD65-4FA5-B0C7-06EBA2F24C42

P698

Q33713689-2ACF31F4-FB75-419A-8D66-3983FAEB6F10

P921

Q33713689-9CC9F282-0076-43C5-8EFA-4A42234535A1

P932

Q33713689-832B3108-F330-48D9-9580-347ABF40389C

P356

P1433

Molecular Therapy

P1476

Nonallele-specific silencing o ...... y in Huntington's disease mice

@en

P2093

Barrie J Carter

http://www.w3.org/2001/XMLSchema#string

Beverly L Davidson

http://www.w3.org/2001/XMLSchema#string

Inês Martins

http://www.w3.org/2001/XMLSchema#string

Jodi L McBride

http://www.w3.org/2001/XMLSchema#string

Shihao Shen

http://www.w3.org/2001/XMLSchema#string

Yi Xing

http://www.w3.org/2001/XMLSchema#string

P2860

Bioconductor: open software development for computational biology and bioinformatics

The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists

Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice

Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes

Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue

Inactivation of the mouse Huntington's disease gene homolog Hdh

siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro

Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

P304

1053-1063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.17

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Ryan L. Boudreau

P577

2009-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19240687

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

2835182

http://www.w3.org/2001/XMLSchema#string